IP Library › Granted Patent US 11,180,533
Granted Patent B2
US 11,180,533 · App. 16/441,238 · Granted Nov 23, 2021

Process for the preparation of Cetrorelix acetate

Inventors: Manik Reddy Pullagurla (Hyderabad, IN); Jagadeesh Babu Rangisetty (Hyderabad, IN)
Assignee: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED
C07K7/23C07K1/063C07K1/065C07K1/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,180,533
App. No.
16/441,238
Granted
Nov 23, 2021
Kind
B2
Abstract

The present invention relates to an improved process for the preparation of Cetrorelix acetate (1). More particularly, the present invention relates to the purification of Cetrorelix acetate (1) by simple method.

Claims (26)

1. A process for the preparation of Cetrorelix acetate

comprising:

a) loading first protected amino acid Fmoc-D-Alanine

on a suitable acid sensitive resin to obtain intermediate

using solid phase synthesizer;

b) deprotecting the Fmoc group of intermediate and coupling intermediate with the required amino acids using a suitable coupling agent in the said order, wherein the order of amino acids are Fmoc-D-alanine, Fmoc-L-proline, Fmoc-D-Arginine(Pbf), Fmoc-L-leucine, Fmoc-D-citruline, Fmoc-O-tert-butyl-L-tyrosine, Fmoc-O-tert-butyl-L-serine, D-3-(3′-pyridyl)-D-alanine, Fmoc-D-4-chlorophenyl alanine, N-acetyl-D-3-(2-naphthyl)alanine to form protected peptide intermediate;

c) cleaving protected peptide intermediate from the resin and deprotecting the side chain protecting groups to yield Cetrorelix trifluoro acetate;

d) purifying Cetrorelix trifluoro acetate by Flash chromatography;

e) converting Cetrorelix trifluoro acetate to Cetrorelix acetate by salt exchange method to obtain pure Cetrorelix acetate.

2. The process as claimed in claim 1 , wherein the amino protecting group is selected from group comprising of Fmoc (9-fluorenyl methoxy carbonyl), Boc (tert-butyloxycarbonyl), Cbz (Benzyloxycarbonyl), Bpoc (2-(4-biphenyl)-2-propyloxycarbonyl), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf).

3. The process as claimed in claim 1 , wherein the hydroxyl protecting group is selected from the group comprising of DMT (dimethoxy trityl), MMT (Methoxytrityl), TRT (Trityl), tert-butyl, t-butoxy carbonyl.

4. The process as claimed in claim 1 , wherein the coupling agent (s) is selected from the group comprising of phosgene, carbonyldiimidazole (CDI), HOBt (Hydroxy benzotriazole), TBTU (0-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate), DCC (1,3-dicyclohexylcarbodiimide), DIC (Diisopropylcarbodiimide), HBTU (O-Benzotriazole-N,N,N′ N-tetramethyluronium hexafluoro phosphate), BOP (Benzotriazol-I-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate), PyBOP (Benzotriazol-1-yloxy tri(pyrrolidino)phosphonium hexafluorophosphate), PyBrOP (Bromotri(pyrrolidino)phosphonium hexafluorophosphate), Chlorotri(pyrrolidino)phosphonium hexafluorophosphate (PyCIOP), Ethyl-2-cyano-2-(hydroxyimino) acetate (Oxyma Pure), 0-(6-Chlorobenzotriazold-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TCTU), Ethyl 1,2-dihydro-2-ethoxyquinoline-1-carboxylate(EEDQ),1-Cyano-2-ethoxy-2oxoethyHdenaminooxy)dimethylamino morpholino carbenium hexafluorophosphate (COMU), 3-(Diethoxy-phosphoryloxy)-3H-benzo[d][1,2,3] triazin-4-one (DEPBT), 1-hydroxy 7-azabenzotriazole (HoAt), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxidhexafluoro phosphate (HATU), dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium tetra fluoroborate (TATU) or mixtures thereof.

5. The process as claimed in claim 1 , wherein the deprotecting agent used is selected from a group comprising of 4 MP (4-methylpiperidine), PP (piperidine), and PZ (piperazine), pyridine, 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), TFA (trifluro acetic acid), TES (Triethyl silane), TIS (Triisopropyl silane), thioanisole, anisole, EDT(Ethanedithiol), phenol, DMS (Dimethyl sulfide), p-cresol, m-cresol or mixtures thereof.

6. A process for the purification of Cetrorelix trifluoroacetate with purity greater than 99.0% by Flash chromatography, which comprises of:

I. mixing Cetrorelix trifluoroacetate salt in a suitable diluent;

II. eluting the sample through cartridge; and

III. isolating pure Cetrorelix trifluoroacetate salt.

7. The process as claimed in claim 6 , wherein the buffer used is selected from trifluoroacetic acid (TFA), o-phosphoric acid (OPA), ammonium acetate buffer or mixtures thereof.

8. A process for the preparation of Cetrorelix acetate with purity greater than 99.0% by converting Cetrorelix trifluoroacetate salt to Cetrorelix acetate salt by desalting and exchanging with suitable salt by passing through resin and acid.

9. The process as claimed in claim 8 , wherein Cetrorelix trifluoroacetate salt is desalted by passing over suitable basic resin selected from macroporous strongly basic anion exchange resin in chloride form with Sty-DVB matrix and Benzyl trimethyl amine as functional group, PolyAPTAC, or poly (acrylamido-N-propyltrimethylammonium chloride) and PolyMAPTAC, or poly[(3-(methacryloylamino)-propyl] trimethylammonium chloride) and suitable acid used is glacial acetic acid.

10. A Cetrorelix acetate having purity greater than 99% by HPLC and wherein one or more of the following

a. less than 1.0% (w/w) of impurity A;

b. less than 1.0% (w/w) of impurity B;

c. less than 1.0% (w/w) of impurity C;

d. less than 1.0% (w/w) of impurity D; and

e. heavy metals less than 10 ppm.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2019
From: PULLAGURLA, MANIK REDDY; RANGISETTY, JAGADEESH BABU
To: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED
Reel/Frame 050849/0005 →
Priority Claims (1)
IN 201841022595 · Jun 16, 2018 · national
Continuity (1)
Related Publication 20190382447A1 · Dec 19, 2019
Cited By (2)
US 12,202,857 US 12,411,064